Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | amidase | 0.0111 | 0.2609 | 0.504 |
Brugia malayi | RNA binding protein | 0.0133 | 0.3621 | 0.3621 |
Onchocerca volvulus | Huntingtin homolog | 0.0127 | 0.3326 | 1 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.5 |
Brugia malayi | hypothetical protein | 0.0127 | 0.3326 | 0.3326 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0111 | 0.2609 | 0.2336 |
Echinococcus multilocularis | tar DNA binding protein | 0.0133 | 0.3621 | 0.3386 |
Brugia malayi | TAR-binding protein | 0.0133 | 0.3621 | 0.3621 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0271 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.3326 | 0.097 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0111 | 0.2609 | 0.2336 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.0688 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0111 | 0.2609 | 0.2336 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0063 | 0.0356 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0111 | 0.2609 | 0.2336 |
Loa Loa (eye worm) | RNA binding protein | 0.0133 | 0.3621 | 0.1369 |
Onchocerca volvulus | Huntingtin homolog | 0.0127 | 0.3326 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0167 | 0.5177 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.0688 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.3326 | 0.097 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0167 | 0.5177 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0133 | 0.3621 | 0.6995 |
Echinococcus granulosus | tar DNA binding protein | 0.0133 | 0.3621 | 0.3386 |
Loa Loa (eye worm) | TAR-binding protein | 0.0133 | 0.3621 | 0.1369 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0133 | 0.3621 | 0.1369 |
Loa Loa (eye worm) | hypothetical protein | 0.0271 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0133 | 0.3621 | 0.3621 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0133 | 0.3621 | 0.6995 |
Brugia malayi | amidase | 0.0111 | 0.2609 | 0.2609 |
Schistosoma mansoni | tar DNA-binding protein | 0.0133 | 0.3621 | 0.6995 |
Schistosoma mansoni | tar DNA-binding protein | 0.0133 | 0.3621 | 0.6995 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0271 | 1 | 1 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0111 | 0.2609 | 0.504 |
Schistosoma mansoni | tar DNA-binding protein | 0.0133 | 0.3621 | 0.6995 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0063 | 0.0356 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 19 nM | Inhibition of HIV1 recombinant wild type reverse transcriptase by SPA heteropolymeric assay | ChEMBL. | 20829038 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.